Group items tagged

Polio has been detected in sewage samples in London, the first sign since the 1980s that the virus could be spreading in the UK, but no cases have been found, authorities said. The risk of infection from the disease, which causes paralysis in children in under one per cent of cases, was also low because of high vaccination rates, the UK Health Security Agency (UKHSA) said. The agency nevertheless encouraged parents to make sure their children were vaccinated after the discovery of the virus during routine wastewater surveillance - particularly those who may have missed shots during the Covid-19 pandemic. Nationwide vaccination levels are above the 90 per cent needed to prevent outbreaks, but London's coverage rates among the under-twos has dipped below that in recent years. NHS England will begin contacting parents of children under five who are not immunised. Polio, spread mainly through contamination by faecal matter, used to kill and paralyse thousands of children annually worldwide. There is no cure, but vaccination brought the world close to ending the wild, or naturally occurring, form of the disease.

The National Institute for Health and Care Excellence (NICE) has issued draft guidance on 'Evusheld' which is not recommended for vulnerable adult with high risk of severe Covid-19 on Thursday (16 February). The draft guidance is open for public consultation until 9 March 2023. The committee will consider any comments received at a meeting currently due to take place on 4 April 2023. It comes after last month's decision by the US drug regulator to withdraw its emergency use authorisation for Evusheld as a preventative treatment for Covid-19, which said there was insufficient evidence that Evusheld is effective against the dominant variants of Covid-19 in the US. NICE's independent appraisal committee has reached the same conclusion having considered evidence which shows Evusheld is unlikely to prevent infection with most of the variants circulating in the UK now and in the near future. It has also announced that it is developing a new review process to update recommendations on the cost-effectiveness of Covid-19 treatments so they can be made available more quickly to patients if they show promise against new variants and are found to be cost-effective.

Lord Markham, a health minister suggested the House of Lords on Tuesday (10 January) that plan of 'using pharmacies more for patient will put funding their way', just like allocation of Covid vaccine provided support. In a statement to the House of Lords he praised the sector saying they are a 'crucial part of the front line'. His statement was in response to a question from Lord Grade, who is campaigning on behalf of the community pharmacy sector. Lord Grade warned Government that it must take action before pharmacies start to close. On Monday (9 January) the Health Secretary, Steve Barclay MP, commented: "There are many more things that community pharmacists can support with that can ease pressure on General Practice. The Primary Care recovery plan will set out a range of additional services that Community Pharmacy can deliver."

Clinical trials for BioNTech's cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company's top executive Ugur Sahin told magazine Der Spiegel. BioNTech, known for its COVID vaccine with U.S. partner Pfizer, is currently deciding which types of cancer it wants to test its personalized cancer immunotherapies on and the locations where it will conduct the trials, Sahin said. The company wants these therapies, which are based on messenger RNA (mRNA) technology similar to the one that underpins its COVID-19 vaccine, to soon become a regular treatment for cancer patients. "We believe that this should be possible for large amounts of patients before 2030," Sahin said.

Titan PMR, a pioneer of cutting pharmacy technology has set up additional new team of 12 staff to cater for a deluge of independent pharmacists investing in new businesses. The company is utilising the opportunity that is underway as large chains look to sell off or close their community pharmacies, offering an opportunity for pharmacists looking to provide efficient dispensing and additional services. In January this year Lloyds Pharmacy, which was bought by a private equity firm in 2022, announced plans to close all its 237 branches inside Sainsbury's stores over the course of 2023. Currently, more than 5,500 of around 14,000 registered pharmacy premises across the UK are owned by corporates and supermarkets. Titan PMR - an innovative, cloud-based system which manages end-to-end pharmacy workflow - has become the preferred software platform especially amongst first time buyers who are keen to offer new services to patients. The new team at the Bristol-based company, hired to support this sector, sees its total workforce growing to more than 50 staff.

A community pharmacist, Viral Doshi was honoured with the British Citizen Award (BCA) on Thursday (26 January) at the Palace of Westminster for transforming his community centre into vaccination hub during Covid-19 pandemic. Viral was presented with his Medal of Honour by Liam Sargeant, Senior Company Communications Manager, from supporters P&G and TV presenter and Patron of the BCA, Nick Knowles, who hosted the event. At the height of the pandemic, Viral obtained approval to transform his community centre into a vaccination hub. Located in the heart of a multi-ethnic population, with social deprivation, surrounded by wards experiencing high rates of Covid-19. His determination to increase uptake and reduce vaccination hesitancy, led to 80,000 vaccinations being administered, the overall highest vaccination uptake in North West London. Viral is a passionate advocate for the role that GP practices and community pharmacies can play in supporting the health agenda. His objective, to provide better choice and access for the community have been fully met and appreciated by patients. His initiatives led to a dramatic increase in the clinical skills, knowledge and services offered by local community pharmacies around a variety of health topics. This enabled pharmacies to adopt a holistic health approach to working with their communities.

The Company Chemists Association (CCA)'s 'Prospectus for community pharmacy' has revealed that community pharmacies can release over 42 million appointments from general practice every year. In its prospect, the association calculated that community pharmacies could reduce hospital readmissions by 65,000 and administer an additional 10m routine vaccines annually. The prospectus sets out bold ideas and proposals regarding the future of community pharmacy. The association said: "Community pharmacies already work collaboratively with the NHS to ensure that patients can access care easily and safely. Whilst the sector has evolved considerably in recent years, the CCA proposes that pharmacies could do even more to directly tackle key problems for patients." CCA is concerned that without immediate action pharmacy closures will become increasingly common. "Fewer pharmacies will considerably diminish access to vital medicines and services, with the greatest impact on those in deprived communities."

An Indian court has sentenced two pharmaceutical company executives to two-and-half years in jail for exporting substandard drugs to Vietnam a decade ago, months after the WHO linked their cough syrups to the deaths of children in Gambia. India suspended production at Maiden Pharmaceuticals in October last year for violations of manufacturing standards after the World Health Organization said four of its cough syrups may have killed dozens of children in Gambia. The company has denied its drugs were at fault for the deaths in Gambia and tests by an Indian government laboratory found there were no toxins in them. The company had been facing legal difficulties for years over suspected shoddy products. A court in Sonipat, near New Delhi, where Maiden has its main production facility, ordered jail for company founder Naresh Kumar Goel and technical director M.K. Sharma for exporting heartburn medicine "not of standard quality" to Vietnam.

The Royal Pharmaceutical Society (RPS) has backed a new framework from NHS England to reduce inappropriate prescribing of addiction-causing medicines. It believes that the new framework is a positive step towards improving patient care by supporting medicine reviews and shared decision making to help people reduce their use of medicines that are no longer providing much clinical benefit. The society has also welcomed investment in innovative approaches to supporting patients and urged all pharmacists to refer people to such schemes. Director for England at RPS, James Davies said: "Pharmacists are well-placed to help reduce inappropriate prescribing of high strength painkillers such as opioids and other addictive medicines. "Pharmacy teams can also often spot repeat purchases of over the counter medicines by patients so are well placed to intervene and give advice on the management of chronic pain. Whilst opioids can play an important part in helping people with chronic pain there has long been a need for alternative approaches that are safer and more effective for patients.

The Pharmaceutical Services Negotiating Committee (PSNC) has raised concerns over the NHS ad campaign highlighting how community pharmacies can support patients with non-health advice amidst the growing pressure on pharmacies. It believes the campaign will only 'worsen' the pressure on pharmacies. "It is always deeply concerning to see campaigns directing people to pharmacies without any regard for the pressures they are under: it is irresponsible and extremely unhelpful," said PSNC Chief Executive Janet Morrison. She called the campaign 'particularly irritating' just weeks after the committee rejected a series of proposals from NHS England and DHSC on relief measures to ease pressure on pharmacies as being totally inadequate. "NHS England Board Members have noted the pressure on pharmacies - so why are their teams so often acting to make these pressures worse? We need to see a radical change in how NHS England treats pharmacies and we're continuing to press for that via our influencing and campaigning work," she added. The NHS launched the new campaign on Monday (27 February) to highlight how high-street pharmacies can support patients with non-urgent health advice for minor conditions including coughs, aches and colds.

While Northern Irish business groups has welcomed the certainty a new EU-UK deal on post-Brexit trade rules for the region provided, the pharmaceutical industry too has expressed cautious optimism. In his speech on the Windsor Framework on Monday (February 28) Prime Minister Rishi Sunak said the agreement "delivers a landmark settlement on medicines". "From now on, drugs approved for use by the UK's medicines regulator will be automatically available in every pharmacy and hospital in Northern Ireland," he announced. The National Pharmacy Association's Northern Ireland manager Anne McAlister expressed a sense of cautious optimism. She said: "While the devil may yet be in the detail, the Windsor Framework would appear to be good news for pharmacies in Northern Ireland. It seems to address the main concerns we have expressed about medicines supplies to NI, but we want to examine the small print to ensure the new arrangements meet the needs of our members and the patients they serve.

Thousands of lung cancer patients in England will benefit from a ground-breaking new drug that can reduce the risk of relapse. This follows a deal brokered by NHS England and approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for atezolizumab therapy to treat non-small cell lung cancer (NSCLC). More than 850 patients are expected to be eligible for the drug in the first year, rising to more than 1000 in the third year. It is the first immunotherapy approved for patients with early-stage NSCLC who have undergone surgery and chemotherapy. Clinical trials have shown that atezolizumab can reduce the risk of cancer relapse or death by 34 per cent in patients with early-stage NSCLC.

Independent charity group, Pharmacist Support has appointed five new trustees to its board - David Downham, Karen Harrowing, Mohammed Hussain, Mala Khiroya, and Alison Scowcroft, for a term of three years. The new recruits will join the existing Board members Anita Cawley, Catherine Harper, Paul Johnson, Steve Lutener, Esther Sadler-Williams, Mark Sweeney and Sarah Willis. Harrowing, Downham and Hussain have begun their 3-year term in January 2022, while Scowcroft and Khiroya would join the board in June. The new appointments are in line with the Charity's plans, announced last year, to enhance its volunteer schemes. "Since the launch of the charity's new strategy in January 2020, the profession has been faced with many new challenges. We are really proud of the work we have done in the last few years to address some of these challenges," said Pharmacist Support chief executive Danielle Hunt.

There is a realistic possibility of large waves of Covid-19 infection in the future in Britain and such waves might even be considered likely, epidemiologists who model the Covid-19 pandemic to inform government advice have said. Prime minister Boris Johnson has ditched legal restrictions in England, saying that, while the pandemic was not over, Britain needs to learn to live with Covid. The Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O) said the emergence of new viral variants was the biggest unknown factor in the medium-to-long term, along with waning population immunity and changes in mixing patterns. "Large future waves of infection that need active management to prevent detrimental pressure on the health and care sector are, at least, a realistic possibility (high confidence) or likely (medium confidence)," SPI-M-O said in a consensus statement published on Friday.

Levomepromazine 25mg/1ml solution for injection will remain unavailable until the week commencing March 7,2022, Department of Health and Social Care (DHSC) said in an update. While alternative medicines for use in palliative care remain available in ample supply to support an uplift in demand, the date supply resumption of Levomepromazine is yet to be confirmed. The DHSC has sent a copy of this medicine supply notification to all pharmacy NHS email addresses. It further informed primary care providers that prescription validation has been temporarily implemented at wholesaler level.

In response to a Scottish government consultation, the National Pharmacy Association (NPA) has called for continued investment to develop community pharmacy teams and create additional capacity in existing services. The consultation examines different ways patients access healthcare services in Scotland and focuses on sources of healthcare other than GPs that exist in the community. The inquiry was discussed with NPA policy leads across the UK, NPA Scottish members and other Scottish pharmacy stakeholder organisations. The NPA stated that services delivered during the pandemic has proven the importance of Scotland's 1,258 community pharmacies, and believes additional capacity for existing pharmacy services, and expansion of pharmacy Public Health Services is possible with continued investment from the government.

The government on Wednesday (March 2) announced an investment of £260 million to support research, development and manufacturing of new drugs, devices and diagnostics. Of the total funding, up to £200m has been allocated for research to better access NHS data through Trusted Research Environments and digital clinical trial services, enabling availability of crucial data with the highest levels of privacy. This will allow the NHS to deliver new life-saving treatments to patients, tackle health inequalities and improve patient care, a government release stated. The remaining £60m will support commercial-scale manufacturing investments by companies at the leading-edge of innovation, from cell and gene therapies and earlier and better diagnostic technologies, to medical devices. The funding for manufacturing investments will be distributed through the new Life Sciences Innovative Manufacturing Fund (LSIMF), following the success of the earlier Medicines and Diagnostics Manufacturing Transformation Fund.

WAGMI or 'we are all gonna make it' is an established abbreviation in the crypto world, and pharmacists can learn from it. To all the dreamers, the visionaries, the go-getters, the futurists - we need you all. In the past few months, since the rebranding of Facebook into Meta, the word 'Metaverse' has become exponentially popular and there is a huge opportunity for pharmacists to get involved. In his popular podcast, Aragorn Meulendijks, the chief marketing officer at Your Open Metaverse - YOM, gave a crystal-clear vision on the unique and valuable possibility of a metaverse pharmacy or metapharmacy. Imagine it is 2030, and there are over a billion users of Virtual Reality headsets. You have recently been hired as the new metaverse pharmacist (metapharmacist) at the global metaverse pharmacy (metapharmacy) "YOMRx". Your patient comes to your metapharmacy with their digital twin (different to digital avatar)where you are able to provide them with medical advice (metaconsultation).

Molnupiravir capsules, which is also known as gamechanger medicine for corona is now available at best price. This effective Covid treatment pill is also available in 200mg/400mg pack at affordable prices. Molnupiravir is latest, effective, safe and affordable corona treatment medicine. It is now available.

The National Institute for Health and Care Excellence (NICE) has recommended elosulfase alfa for routine use in the NHS for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome). Elosulfase alfa, also called Vimizin and made by BioMarin, becomes the first disease modifying treatment recommended by NICE for routine NHS use for people with this rare, severely life-limiting condition. NICE's final draft guidance follows the collection of 'real-world' data from 69 people who received NHS-funded treatment since 2015 as part of a managed access agreement. Clinical trial evidence and data collected as part of the managed access agreement, along with expert clinical opinion, shows some long-term benefits with elosulfase alfa treatment which suggest it slows progression of MPS 4A.